These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37996012)

  • 21. Design, synthesis and biological evaluation of caudatin analogs as potent hepatitis B virus inhibitors.
    Wang LJ; Chen H; Ma YB; Huang XY; Geng CA; Zhang XM; Chen JJ
    Med Chem; 2015; 11(2):165-79. PubMed ID: 25181984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tropolone and its derivatives as inhibitors of the helicase activity of hepatitis C virus nucleotide triphosphatase/helicase.
    Borowski P; Lang M; Haag A; Baier A
    Antivir Chem Chemother; 2007; 18(2):103-9. PubMed ID: 17542155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ongoing viral replication and production of infectious virus in patients with chronic hepatitis B virus suppressed below the limit of quantitation on long-term nucleos(t)ide therapy.
    Burdette DL; Lazerwith S; Yang J; Chan HLY; Delaney Iv WE; Fletcher SP; Cihlar T; Feierbach B
    PLoS One; 2022; 17(4):e0262516. PubMed ID: 35363817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-nucleoside hepatitis B virus polymerase inhibitors identified by an in vitro polymerase elongation assay.
    Nakajima S; Watashi K; Fukano K; Tsukuda S; Wakae K; Aizaki H; Muramatsu M; Wakita T; Toyoda T
    J Gastroenterol; 2020 Apr; 55(4):441-452. PubMed ID: 31768802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis B Virus Capsid Assembly Modulators, but Not Nucleoside Analogs, Inhibit the Production of Extracellular Pregenomic RNA and Spliced RNA Variants.
    Lam AM; Ren S; Espiritu C; Kelly M; Lau V; Zheng L; Hartman GD; Flores OA; Klumpp K
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis and primary biological evaluation of the novel 2-pyridone derivatives as potent non-nucleoside HBV inhibitors.
    Jia H; Song Y; Yu J; Zhan P; Rai D; Liang X; Ma C; Liu X
    Eur J Med Chem; 2017 Aug; 136():144-153. PubMed ID: 28494252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protection by tropolones against H2O2-induced DNA damage and apoptosis in cultured Jurkat cells.
    Doulias PT; Nousis L; Zhu BZ; Frei B; Galaris D
    Free Radic Res; 2005 Feb; 39(2):125-35. PubMed ID: 15763960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Screening and identification of compounds with antiviral activity against hepatitis B virus using a safe compound library and novel real-time immune-absorbance PCR-based high throughput system.
    Lamontagne J; Mills C; Mao R; Goddard C; Cai D; Guo H; Cuconati A; Block T; Lu X
    Antiviral Res; 2013 Apr; 98(1):19-26. PubMed ID: 23415884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide.
    Kaneko M; Watashi K; Kamisuki S; Matsunaga H; Iwamoto M; Kawai F; Ohashi H; Tsukuda S; Shimura S; Suzuki R; Aizaki H; Sugiyama M; Park SY; Ito T; Ohtani N; Sugawara F; Tanaka Y; Mizokami M; Sureau C; Wakita T
    J Virol; 2015 Dec; 89(23):11945-53. PubMed ID: 26378168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel fluoronucleoside analog NCC inhibits lamivudine-resistant hepatitis B virus in a hepatocyte model.
    Zhang J; Wang Y; Peng Y; Qin C; Liu Y; Li J; Jiang J; Zhou Y; Chang J; Wang Q
    Braz J Infect Dis; 2018; 22(6):477-486. PubMed ID: 30586543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, diversity-oriented synthesis and biological evaluation of novel heterocycle derivatives as non-nucleoside HBV capsid protein inhibitors.
    Jia H; Yu J; Du X; Cherukupalli S; Zhan P; Liu X
    Eur J Med Chem; 2020 Sep; 202():112495. PubMed ID: 32712535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficient Inhibition of Hepatitis B Virus (HBV) Replication and cccDNA Formation by HBV Ribonuclease H Inhibitors during Infection.
    Chauhan R; Li Q; Woodson ME; Gasonoo M; Meyers MJ; Tavis JE
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0146021. PubMed ID: 34516242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phytomedicines to Target Hepatitis B Virus DNA Replication: Current Limitations and Future Approaches.
    Sadiea RZ; Sultana S; Chaki BM; Islam T; Dash S; Akter S; Islam MS; Kazi T; Nagata A; Spagnuolo R; Mancina RM; Hossain MG
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of Antiviral Agents Targeting Hepatitis B Virus Promoter from Extracts of Indonesian Marine Organisms by a Novel Cell-Based Screening Assay.
    Yamashita A; Fujimoto Y; Tamaki M; Setiawan A; Tanaka T; Okuyama-Dobashi K; Kasai H; Watashi K; Wakita T; Toyama M; Baba M; de Voogd NJ; Maekawa S; Enomoto N; Tanaka J; Moriishi K
    Mar Drugs; 2015 Nov; 13(11):6759-73. PubMed ID: 26561821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis and evaluation of pyrazole derivatives as non-nucleoside hepatitis B virus inhibitors.
    Jia H; Bai F; Liu N; Liang X; Zhan P; Ma C; Jiang X; Liu X
    Eur J Med Chem; 2016 Nov; 123():202-210. PubMed ID: 27484509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nobiletin, a novel inhibitor, inhibits HBsAg production and hepatitis B virus replication.
    Hu Z; Hu J; Ren F; Xu H; Tan M; Wang Q; Ren J
    Biochem Biophys Res Commun; 2020 Mar; 523(3):802-808. PubMed ID: 31954513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of FDA-approved drugs that target hepatitis B virus transcription.
    van de Klundert MA; Zaaijer HL; Kootstra NA
    J Viral Hepat; 2016 Mar; 23(3):191-201. PubMed ID: 26456011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Searching for a new anti-HCV therapy: synthesis and properties of tropolone derivatives.
    Boguszewska-Chachulska AM; Krawczyk M; Najda A; Kopańska K; Stankiewicz-Drogoń A; Zagórski-Ostoja W; Bretner M
    Biochem Biophys Res Commun; 2006 Mar; 341(2):641-7. PubMed ID: 16438939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The furan route to tropolones: probing the antiproliferative effects of β-thujaplicin analogs.
    Oblak EZ; Bolstad ES; Ononye SN; Priestley ND; Hadden MK; Wright DL
    Org Biomol Chem; 2012 Nov; 10(43):8597-604. PubMed ID: 23032214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.